1. India Stocks

  2. •

    Consumer non-durables

  3. •

    Food: specialty/candy
Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd

248.35
INR
-10.50
(-4.06%)
15.33EPS
20.75P/E
34.43BMarket Cap
Nov 06Next Earn
Advanced Enzyme Technologies Ltd
NSE:ADVENZYMES
(National Stock Exchange of India)

Recent

price

248.35

P/E

ratio

20.75

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
11.2
16.52
20.6
19.71
20.41
26.89
29.69
34.75
37.42
39.54
44.8
47.32
48.33
55.76
56.91
66.57
66.97
Revenue per Share
1.61
3.26
4.68
1.81
4.68
6.97
8.27
8.07
9.95
11.58
13.06
10.7
9.45
11.92
11.72
15.08
14.82
Basic EPS, GAAP
-2.31
-10.81
0.93
4.22
3.32
7.79
8.76
9.53
10.41
8.08
12.84
8.42
9.14
8.85
9.63
9.33
- -
Free Cash Flow per Basic Share
0.01
0.12
0.27
0.37
0.16
0.33
0.23
0.68
0.72
0.94
0.71
1.06
1.12
5.07
5.28
5.34
- -
Dividend per Share
6.1
9.34
15.01
15.38
19.48
30.39
41.57
50.08
60.8
75.18
86.9
97.37
110.45
118.41
127
145.81
- -
Book Value per Share
6.09
-5.59
-0.68
-0.33
3.41
9.65
18.14
20.3
30.4
43.07
54.38
64.96
76.31
84.11
92.52
108.6
- -
Tangible Book Value per Share
104
104
107
109
109
109
111
112
112
112
112
112
112
112
112
112
112
Basic Weighted Avg Shares
1,161
1,713
2,194
2,145
2,221
2,926
3,287
3,879
4,177
4,416
5,004
5,289
5,404
6,235
6,365
7,450
7,496
Sales/Revenue/Turnover
16.18
34.03
38.44
32.87
37.11
44.72
42.82
38.63
39.44
40.58
41.86
31.87
25.59
27.72
25.23
25.78
24.44
Operating Margin (%)
50
55
74
100
90
87
128
183
211
258
287
350
350
352
366
401
404
Depreciation Expense
167
338
498
197
510
759
915
901
1,111
1,293
1,459
1,196
1,056
1,333
1,311
1,687
1,659
Net Income, GAAP
11.65
28.36
34.2
26.17
30.74
35.06
32.18
32.68
28.44
25.74
28
27.63
26.02
27.08
28.5
25.34
25.7
Effective Tax Rate (%)
14.36
19.71
22.7
9.2
22.95
25.92
27.86
23.22
26.59
29.28
29.16
22.61
19.55
21.38
20.6
22.65
22.13
Profit Margin (%)
184
-280
-82
-406
-266
268
777
1,119
2,169
3,160
4,485
5,399
6,435
7,031
7,836
9,369
- -
Working Capital
370
1,394
1,167
879
540
388
195
198
70
120
138
265
224
228
209
117
- -
LT Debt
645
984
1,657
1,711
2,164
3,359
4,852
5,817
7,048
8,674
10,326
11,404
12,842
13,711
14,687
16,831
- -
Total Equity
- -
18.97
16.96
8.88
17.01
21.21
19.43
16.48
16.68
16.09
15.36
10.93
7.83
8.25
7.75
9.33
- -
Return on Invested Capital (%)
- -
19.25
16.71
7.29
16.63
20.64
18.99
15.12
15.7
15.54
14.45
10.44
8.76
9.63
8.94
10.29
- -
Return on Capital (%)
- -
42.17
38.29
11.93
26.87
27.95
23.04
17.6
17.94
17.03
16.12
11.61
9.09
10.42
9.55
11.05
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
204
- -
LT Borrowings
- -
79
- -
LT Finance Leases
- -
38
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
112
112
112
Market Capitalization
33,830
28,575
34,433

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
10,436
- -
Cash, Cash Equivalents & STI
- -
7,072
- -
Accounts Receivable, Net
- -
1,450
- -
Inventories
- -
1,773
- -
Total Current Liabilities
- -
1,067
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
204
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.91%
10.31%
14.6%
Free Cash Flow
4.66%
-4.64%
-3.08%
Net Income, GAAP
9.52%
4.7%
28.68%
Sales/Revenue/Turnover
9.94%
8.47%
17.04%
Total Cash Common Dividend
59.65%
82.38%
1.27%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,545
1,461
1,691
1,672
6,365
2026
1,859
1,845
1,719
2,034
7,450
2027
1,898
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
3.05
2.94
3.36
2.37
11.72
2026
3.57
3.87
3.8
3.84
15.08
2027
3.31
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
5.28
2026
- -
- -
- -
- -
5.34
2027
- -
- -
- -
- -
- -
Similar Companies
PepsiCo, Inc. (NASDAQ:PEP)
Britannia Industries Ltd (NSE:BRITANNIA)
Tata Consumer Products Limited (NSE:TATACONSUM)
Ulker Biskuvi Sanayi A.S. (BIST:ULKER)
Mondelez International, Inc. (NASDAQ:MDLZ)
The Hershey Company (NYSE:HSY)
Business
Advanced Enzyme Technologies Limited is an India-based biotech company primarily engaged in the research, development, manufacturing, and marketing of enzyme and probiotic products. The company offers over 400 proprietary products derived from more than 65 indigenous enzymes and probiotics. It serves multiple industries, including human healthcare and nutrition, animal nutrition, baking, fruit and vegetable processing, brewing and malting, grain processing, protein modification, dairy processing, specialty applications, textile processing, leather processing, paper and pulp processing, biofuels, biomass processing, and biocatalysis. Key product categories include nutraceuticals; food and feed enzymes; dietary supplements; functional beverages and foods; and specialty enzymes like Addzyme CALB, which is a food-grade lipase enzyme used in triglyceride hydrolysis. Founded in 1989 and headquartered in Nashik, Maharashtra, India, Advanced Enzyme Technologies operates globally with a focus on eco-safe biochemical solutions. Recent strategic developments include the acquisition and equity investment in its wholly owned subsidiary Advanced Nutrazyme Private Limited, aimed at expanding its presence in the nutraceutical segment. The company has also been actively enhancing its renewable energy usage and sustainability initiatives, including the installation of solar power plants at its manufacturing facilities. Additionally, it pursues new product launches and broadens its geographical footprint to capture emerging market opportunities. Advanced Enzyme Technologies is noted for its strong research and development focus driving innovation across its enzyme and probiotic product portfolio. The enterprise is positioned as a leader in enzyme technology with operational footholds and markets across India and international regions. It targets diverse customers ranging from large-scale food processing firms and pharmaceutical companies to animal nutrition providers, positioning itself as a comprehensive solutions provider in enzymology and related biotechnologies. Overall, the company combines a legacy of over three decades with modern strategic expansions in product lines and sustainable operational practices to maintain and grow its market leadership in the enzyme manufacturing and nutraceuticals sectors.